Get in Touch

Loading contact form...
Museum of Science

AI and the Future of Cancer Treatments: A Reno Family Foundation Symposium

May 28

7:00pm - 9:00pm

Museum of Science

1 Science Park, Boston, MA 02114

Speakers
Sophia Shalhout, PhD

Sophia Shalhout, PhD, is an Assistant Professor of Otolaryngology – Head and Neck Surgery at Harvard Medical School and a Principal Investigator at the Mike Toth Cancer Research Center at Mass Eye and Ear. Her groundbreaking research applies AI and big data analytics to complex biomedical data, with the goal of advancing personalized medicine for high-risk cancer patients.

Dr. Shalhout’s work goes beyond improving individual treatment plans- she is also using AI to accelerate the discovery of new therapies that target some of the most challenging, traditionally “undruggable” cancer proteins. By optimizing molecular interactions and drug-like properties, her approach merges computational biology with lab-based validation, opening doors to entirely new treatment options for deadly cancers.

Through presentation and conversation, Dr. Shalhout will share how these powerful technologies are reshaping the landscape of cancer care- from precision medicine to faster, smarter drug development.

Don’t miss this opportunity to hear firsthand from one of the leading minds at the intersection of AI and oncology- where innovation meets impact.


Sophia Shalhout, PhD. Sophia Shalhout, PhD, is an Assistant Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School and a Principal Investigator, Assistant Professor in the Mike Toth Cancer Research Center at Mass Eye and Ear. Dr. Shalhout’s research focuses on applying novel artificial intelligence (AI) and big data analytics to multi-scale biomedical clinical data. This research aims to advance personalized medicine for high-risk cancer patients. In addition, Dr. Shalhout also leverages AI to discover novel cancer therapies and treatments targeting traditionally undruggable proteins by optimizing drug-like properties and molecular interactions, significantly accelerating the drug discovery process. Her innovative approach bridges computational biology with experimental validation to overcome the limitations of conventional drug discovery and provide new treatment options for deadly cancers.